The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Cevostamab plus pomalidomide after BCMA-directed therapy in R/R multiple myeloma
Rakesh Popat, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, discusses the potential role of cevostamab plus pomalidomide following BCMA-directed therapy in patients with relapsed/refractory (R/R) multiple myeloma. He highlights the potential efficacy of the combination after BCMA antibody-drug conjugates or CAR T-cell therapy, while noting lower response rates following BCMA bispecific antibodies and the potential impact of immune dysfunction in this setting. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
